{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-091235","form_type":"8-K","ticker":"OSTX","cik":"0001795091","company_name":"OS Therapies Inc","filed_at":"2024-10-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.657108+00:00","generated_at":"2026-05-30T09:46:49.360316+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"OS Therapies appoints two new independent directors; Chairman Goddard and Joacim Borg resign","bullets":["Colin Goddard (Chairman) and Joacim Borg resigned effective Oct 28, 2024; no disagreement with company operations.","Avril McKean Dieser appointed independent director; VP, Head Legal Patient Evidence at UCB; regulatory/commercialization expertise.","Olivier R. Jarry appointed independent director; co-founder/CEO of Libera Bio; 40+ years biopharma experience.","Company preparing for FDA discussion on pivotal trial of OST-HER2 for osteosarcoma; building infrastructure for potential commercial launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-091235","json":"https://secwatch.observer/filing/0001213900-24-091235.json","markdown":"https://secwatch.observer/filing/0001213900-24-091235.md","text":"https://secwatch.observer/filing/0001213900-24-091235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1795091/000121390024091235/0001213900-24-091235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1795091/000121390024091235/ea0218797-8k_osthera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T09:46:49.360316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07c2c775b7","claim":"Colin Goddard resigned as Chairman of the Board and director at OS Therapies Inc.","evidence_excerpt":"Effective October 28, 2024, Colin Goddard, Ph.D. notified the Board of Directors (the “Board”) of the Company of his resignation as the Chairman of the Board and director of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1795091/000121390024091235/0001213900-24-091235-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chairman of the Board and director"}],"fact_type":"executive_change"},{"claim_id":"49db54f5d9","claim":"Joacim Borg resigned as director at OS Therapies Inc.","evidence_excerpt":"Also, effective October 28, 2024, Joacim Borg notified the Board of his resignation as a director, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1795091/000121390024091235/0001213900-24-091235-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"6850ceece2","claim":"Avril McKean Dieser was appointed as director at OS Therapies Inc.","evidence_excerpt":"Avril McKean Dieser and Olivier R. Jarry joined the Board, effective October 28, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1795091/000121390024091235/0001213900-24-091235-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"7d774a8975","claim":"Olivier R. Jarry was appointed as director at OS Therapies Inc.","evidence_excerpt":"Avril McKean Dieser and Olivier R. Jarry joined the Board, effective October 28, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1795091/000121390024091235/0001213900-24-091235-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}